SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer

Name No. For Patients with Purpose
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer 18-33

medically inoperable, early stage, high-risk centrally located non small cell lung cancer.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.


TERAVOLT

Name No. For Patients with Purpose
TERAVOLT CTRIAL-IE 20-02

thoracic cancer and a COVID infection

This registry collects data on patients who have a thoracic cancer and are infected with COVID-19


AbbVie M14-239

Name No. For Patients with Purpose
AbbVie M14-239 18-49

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).


MK3475-671

Name No. For Patients with Purpose
MK3475-671 17-37

Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

To assess the efficacy and safety of Pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants With resectable stage IIB or IIIA non-small cell lung cancer.